Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesActivating and inhibitory IgG Fc receptors on human DCs mediate opposing functionsAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaRituximab: mechanism of actionGraft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptorThe antiinflammatory activity of IgG: the intravenous IgG paradoxTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalObinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerCritical appraisal of rituximab in the maintenance treatment of advanced follicular lymphomaSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesFc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseasesNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyThe role of Fc-FcγR interactions in IgG-mediated microbial neutralizationLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsComplement in monoclonal antibody therapy of cancerTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityTranslating basic mechanisms of IgG effector activity into next generation cancer therapiesTargeting the Fc receptor in autoimmune diseaseTumor antigen-specific monoclonal antibodies and induction of T-cell immunityNew antibody approaches to lymphoma therapyGermline pharmacogenomics in oncology: decoding the patient for targeting therapyMonoclonal antibodies for the treatment of cancerTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytesStructural characterization of a human Fc fragment engineered for lack of effector functionsStructural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling ComplexesNatural killer cells in human cancer: from biological functions to clinical applicationsAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateFc gamma receptors: glycobiology and therapeutic prospectsTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabAttainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaPharmacogenetics in inflammatory bowel diseaseCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors
P2860
Q21131216-2D98910B-698C-42B3-A8B0-CC3F55C50ACFQ24532135-B7676423-2053-4F95-B56F-EF1C7255008AQ24602657-617E9AC4-909D-48FE-83F0-C5343B29AFD5Q24607358-F2EA1C8B-CE8A-4388-AC12-C5B6C5EE765EQ24670205-56E6516F-5B7F-446B-A40C-DC6E388CE90CQ24676548-1D99829F-41A8-4F4B-AA98-83625ECF8188Q24681992-F9D106C0-58CB-46F5-91CD-E42EF349C7E4Q26751002-0E9BF5E4-49D2-48DC-A913-4271ACACB54CQ26765115-4E4FCEC0-6BB9-486A-982F-9BDC52DDCF7DQ26774678-F163CDF6-7AD0-4D4B-82A2-53C1DFCB2574Q26775837-DBB612E5-800F-402F-A6A9-F05AC06E374EQ26776308-A9B9F21F-890A-4299-8C40-3C41B656AD37Q26783175-A23A463D-09B4-4AB8-ADA1-3EECC55B79D4Q26797345-C98B7ED9-24AE-4662-8CAE-C5049C370BB1Q26797466-17C5883A-1B36-4C45-8F81-E078EA0FD416Q26849243-569AF102-901D-48B9-A981-6E297769EA53Q26852287-830A05FE-9528-4B6B-9861-A520B2178F2DQ26860800-084F917F-7A50-4714-A61E-339EED7055EFQ26862220-7C21DFD4-55B0-4D4A-BC39-66BC505A4BABQ26991899-5C5BC9FB-1E34-45E4-B990-CCD2ADFAF860Q27002843-A30568FB-FE24-4E12-A776-9F2B1573CD05Q27009908-04AC7912-D75D-4C93-B1C2-B74217D38832Q27022373-A3151D18-5DD2-460D-B4D6-564D7B09512FQ27022557-182496F9-F12F-499D-B624-ED20439D1B25Q27025966-84168106-C268-4E30-95EC-90A0F16B8126Q27026161-8D1D4DE4-E5F1-4FDF-8246-03ECC8F0E6BCQ27314948-7A785CB8-5AF5-4F0E-A668-FC4CC948D42BQ27341786-1CA57543-BD66-4811-BC26-2931043F1F2EQ27650876-88DC4284-FFC7-4117-AA5D-58D9ED28540FQ27671845-F40C82AD-04CA-4F5F-A606-AC84C7640961Q27691427-A95726CA-F2D1-4E94-AE39-BBDF4BFAD109Q27694769-C03CC119-2F94-4CD1-9F94-7D3EF3C70B2CQ27851876-ADBF8B99-D157-4EFD-94D0-EFB9FACBE86FQ28069362-10CED465-1B85-4794-B308-13F125CC7469Q28076147-87D78708-B0F6-416B-84BB-F790E7944B13Q28076303-FDA8ABF3-9642-46F2-A1C9-574D1D0A6762Q28078993-0D0A1B12-A409-4EC5-B530-8014C62B0CE0Q28237372-CACEE076-05E5-4055-A8A0-81A70D436D3FQ28246002-87510E52-2C83-417C-B7EF-5729F8FC229AQ28537997-3FFC2784-BC0A-4775-BEF1-A604C3FA0823
P2860
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Two immunoglobulin G fragment ...... ents with follicular lymphoma.
@en
type
label
Two immunoglobulin G fragment ...... ents with follicular lymphoma.
@en
prefLabel
Two immunoglobulin G fragment ...... ents with follicular lymphoma.
@en
P356
P1476
Two immunoglobulin G fragment ...... ents with follicular lymphoma.
@en
P2093
Ronald Levy
Wen-Kai Weng
P304
P356
10.1200/JCO.2003.05.013
P407
P577
2003-09-15T00:00:00Z